Education
About Us
Working with TipRanks
Follow Us
Neuronetics (STIM)
:STIM
STIM Stock Chart & Stats
$1.39
-$0.02(-1.30%)
At close: 4:00 PM EST
$1.39
-$0.02(-1.30%)
Day’s Range― - ―
52-Week Range$1.23 - $5.92
Previous CloseN/A
Volume92.55K
Average Volume (3M)2.08M
Market Cap
$113.00M
Enterprise Value$243.86M
Total Cash (Recent Filing)$34.65M
Total Debt (Recent Filing)$90.75M
Price to Earnings (P/E)―
Beta1.33
Next Earnings
Mar 10, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding68,485,920
10 Day Avg. Volume1,264,623
30 Day Avg. Volume2,082,601
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)1.84
Price to Sales (P/S)0.68
P/FCF Ratio-1.57
Enterprise Value/Market Cap2.16
Enterprise Value/Revenue1.88
Enterprise Value/Gross Profit3.72
Enterprise Value/Ebitda-7.14
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.57
Revenue Forecast (FY)$149.83M
Bulls Say, Bears Say
Bulls Say
Business ModelThe company is already beginning to realize the benefits of its new model, with these types of locations seeing roughly 3x the revenue compared to the prior model.
EarningsThe company beat estimates with $38.1M in revenue, driven by $23.0M in Clinic/Greenbrook, which exceeded expectations.
Future GrowthManagement updated its FY25 guidance, raising the low-end of its revenue range, indicating confidence in future growth.
Bears Say
Cash FlowThe stock traded off on the higher-than-expected cash burn for Q1.
Core Segment PerformanceWeakness in the core Neuronetics segment was driven primarily by treatment session revenues, partly offset by system sales.
Gross MarginManagement ultimately lowered gross margin guidance as Greenbrook will be a bigger piece of overall revenue than initially expected.
Neuronetics News
STIM FAQ
What was Neuronetics’s price range in the past 12 months?
Neuronetics lowest stock price was $1.23 and its highest was $5.92 in the past 12 months.
What is Neuronetics’s market cap?
Neuronetics’s market cap is $113.00M.
When is Neuronetics’s upcoming earnings report date?
Neuronetics’s upcoming earnings report date is Mar 10, 2026 which is in 82 days.
How were Neuronetics’s earnings last quarter?
Neuronetics released its earnings results on Nov 04, 2025. The company reported -$0.13 earnings per share for the quarter, missing the consensus estimate of -$0.125 by -$0.005.
Is Neuronetics overvalued?
According to Wall Street analysts Neuronetics’s price is currently Overvalued.
Does Neuronetics pay dividends?
Neuronetics does not currently pay dividends.
What is Neuronetics’s EPS estimate?
Neuronetics’s EPS estimate is -0.11.
How many shares outstanding does Neuronetics have?
Neuronetics has 68,485,920 shares outstanding.
What happened to Neuronetics’s price movement after its last earnings report?
Neuronetics reported an EPS of -$0.13 in its last earnings report, missing expectations of -$0.125. Following the earnings report the stock price went up 3.61%.
Which hedge fund is a major shareholder of Neuronetics?
Currently, no hedge funds are holding shares in STIM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Neuronetics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
STIM Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 536.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 5.5%
Last 30 Days ▼ 5.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
51.37%
12-Months-Change
Fundamentals
Return on Equity
-239.53%
Trailing 12-Months
Asset Growth
96.26%
Trailing 12-Months
Company Description
Neuronetics
Neuronetics, Inc. is a medical technology company focused on developing and commercializing innovative non-invasive therapies for psychiatric and neurological disorders. The company operates primarily in the mental health sector and is best known for its flagship product, the NeuroStar Advanced Therapy System, which utilizes transcranial magnetic stimulation (TMS) to treat major depressive disorder. Neuronetics aims to improve patient outcomes through its evidence-based treatment options, providing healthcare professionals with advanced tools to enhance mental health care.
STIM Company Deck
STIM Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlighted strong revenue growth driven by the Greenbrook clinics and improvements in cash flow management. However, the decline in NeuroStar revenue, decreased gross margins, and reduced guidance for the full year indicate challenges. Despite progress in operational efficiencies and strategic partnerships, the sentiment remains cautious due to these headwinds.View all STIM earnings summariesTechnical Analysis
Ownership Overview
12.56% Insiders
5.80% Mutual Funds
7.57% Other Institutional Investors
67.95% Public Companies and
Individual Investors